Molecular approach to genetic and epigenetic pathogenesis of early-onset colorectal cancer

World Journal of Gastrointestinal Oncology

Volumn 8, Issue 1, 2016, Pages 83-98

  Tezcan, Gulcin ^a   Tunca, Berrin ^a   Ak, Secil ^a   Cecener, Gulsah ^a   Egeli, Unal ^a  

^a ULUDAG UNIVERSITY   (Turkey)

Author keywords

Clinical outcome; Colorectal cancer; Early onset; Epigenetic mechanism; Genetic mechanism

Indexed keywords

EID: 85009506100     PISSN: None     EISSN: 19485204     Source Type: Journal    
DOI: 10.4251/wjgo.v8.i1.83     Document Type: Article

References (176)

1. 1 Sameer AS. Colorectal cancer: molecular mutations and polymorphisms. Front Oncol2013; 3: 114 [PMID: 23717813 DOI: 10.3389/fonc.2013.00114]
2. 2 Vainio H, Miller AB. Primary and secondary prevention in colorectal cancer. Acta Oncol2003; 42: 809-815 [PMID: 14968941]
3. 3 Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin2013; 63: 11-30 [PMID: 23335087 DOI: 10.3322/caac.21166]
4. 4 Nishihara R, Wu K, Lochhead P, Morikawa T, Liao X, Qian ZR, Inamura K, Kim SA, Kuchiba A, Yamauchi M, Imamura Y, Willett WC, Rosner BA, Fuchs CS, Giovannucci E, Ogino S, Chan AT. Long-term colorectal-cancer incidence and mortality after lower endoscopy. N Engl J Med2013; 369: 1095-1105 [PMID: 24047059 DOI: 10.1056/NEJMoa1301969]
5. 5 Shaukat A, Mongin SJ, Geisser MS, Lederle FA, Bond JH, Mandel JS, Church TR. Long-term mortality after screening for colorectal cancer. N Engl J Med2013; 369: 1106-1114 [PMID: 24047060 DOI: 10.1056/NEJMoa1300720]
6. 6 Quirke P, Risio M, Lambert R, von Karsa L, Vieth M. European guidelines for quality assurance in colorectal cancer screening and diagnosis. First Edition–Quality assurance in pathology in colorectal cancer screening and diagnosis. Endoscopy2012; 44 Suppl 3: SE116-SE130 [PMID: 23012115]
7. 7 Minardi AJ, Sittig KM, Zibari GB, McDonald JC. Colorectal cancer in the young patient. Am Surg1998; 64: 849-853 [PMID: 9731812]
8. 8 Parramore JB, Wei JP, Yeh KA. Colorectal cancer in patients under forty: presentation and outcome. Am Surg1998; 64: 563-567; discussion 567-568 [PMID: 9619179]
9. 9 Ogino S, Goel A. Molecular classification and correlates in colorectal cancer. J Mol Diagn2008; 10: 13-27 [PMID: 18165277 DOI: 10.2353/jmoldx.2008.070082]
10. 10 Perea J, Alvaro E, Rodríguez Y, Gravalos C, Sánchez-Tomé E, Rivera B, Colina F, Carbonell P, González-Sarmiento R, Hidalgo M, Urioste M. Approach to early-onset colorectal cancer: clinicopathological, familial, molecular and immunohistochemical characteristics. World J Gastroenterol2010; 16: 3697-3703 [PMID: 20677343]
11. 11 Losi L, Di Gregorio C, Pedroni M, Ponti G, Roncucci L, Scarselli A, Genuardi M, Baglioni S, Marino M, Rossi G, Benatti P, Maffei S, Menigatti M, Roncari B, Ponz de Leon M. Molecular genetic alterations and clinical features in early-onset colorectal carcinomas and their role for the recognition of hereditary cancer syndromes. Am J Gastroenterol2005; 100: 2280-2287 [PMID: 16181381]
12. 12 Fairley TL, Cardinez CJ, Martin J, Alley L, Friedman C, Edwards B, Jamison P. Colorectal cancer in U.S. adults younger than 50 years of age, 1998-2001. Cancer2006; 107: 1153-1161 [PMID: 16862554]
13. 13 Savas N, Dagli U, Akbulut S, Yuksel O, Sahin B. Colorectal cancer localization in young patients: should we expand the screening program? Dig Dis Sci2007; 52: 798-802 [PMID: 17245629]
14. 14 You YN, Xing Y, Feig BW, Chang GJ, Cormier JN. Young-onset colorectal cancer: is it time to pay attention? Arch Intern Med2012; 172: 287-289 [PMID: 22157065 DOI: 10.1001/archinternmed.2011. 602]
15. 15 Calin GA, Gafà R, Tibiletti MG, Herlea V, Becheanu G, Cavazzini L, Barbanti-Brodano G, Nenci I, Negrini M, Lanza G. Genetic progression in microsatellite instability high (MSI-H) colon cancers correlates with clinico-pathological parameters: A study of the TGRbetaRII, BAX, hMSH3, hMSH6, IGFIIR and BLM genes. Int J Cancer2000; 89: 230-235 [PMID: 10861498]
16. 16 Silla IO, Rueda D, Rodríguez Y, García JL, de la Cruz Vigo F, Perea J. Early-onset colorectal cancer: a separate subset of colorectal cancer. World J Gastroenterol2014; 20: 17288-17296 [PMID: 25516639 DOI: 10.3748/wjg.v20.i46.17288]
17. 17 Lynch HT, Shaw TG. Practical genetics of colorectal cancer. Chin Clin Oncol2013; 2: 12 [PMID: 25841492 DOI: 10.3978/j.issn.2304-3865.2013.03.04]
18. 18 Hampel H, Frankel WL, Martin E, Arnold M, Khanduja K, Kuebler P, Clendenning M, Sotamaa K, Prior T, Westman JA, Panescu J, Fix D, Lockman J, LaJeunesse J, Comeras I, de la Chapelle A. Feasibility of screening for Lynch syndrome among patients with colorectal cancer. J Clin Oncol2008; 26: 5783-5788 [PMID: 18809606 DOI: 10.1200/JCO.2008.17.5950]
19. 19 Rodriguez-Bigas MA, Boland CR, Hamilton SR, Henson DE, Jass JR, Khan PM, Lynch H, Perucho M, Smyrk T, Sobin L, Srivastava S. A National Cancer Institute Workshop on Hereditary Nonpolyposis Colorectal Cancer Syndrome: meeting highlights and Bethesda guidelines. J Natl Cancer Inst1997; 89: 1758-1762 [PMID: 9392616]
20. 20 Vasen HF, Watson P, Mecklin JP, Lynch HT. New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative group on HNPCC. Gastroenterology1999; 116: 1453-1456 [PMID: 10348829]
21. 21 Umar A, Boland CR, Terdiman JP, Syngal S, de la Chapelle A, Rüschoff J, Fishel R, Lindor NM, Burgart LJ, Hamelin R, Hamilton SR, Hiatt RA, Jass J, Lindblom A, Lynch HT, Peltomaki P, Ramsey SD, Rodriguez-Bigas MA, Vasen HF, Hawk ET, Barrett JC, Freedman AN, Srivastava S. Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst2004; 96: 261-268 [PMID: 14970275]
22. 22 Bellizzi AM, Frankel WL. Colorectal cancer due to defciency in DNA mismatch repair function: a review. Adv Anat Pathol2009; 16: 405-417 [PMID: 19851131 DOI: 10.1097/PAP.0b013e3181bb6bdc]
23. 23 Tunca B, Pedroni M, Cecener G, Egeli U, Borsi E, Zorluoglu A, Di Gregorio C, Yilmazlar T, Yerci O, de Leon MP. Analysis of mismatch repair gene mutations in Turkish HNPCC patients. Fam Cancer2010; 9: 365-376 [PMID: 20373145 DOI: 10.1007/s10689-010-9336-7]
24. 24 Lastella P, Patruno M, Forte G, Montanaro A, Di Gregorio C, Sabbà C, Suppressa P, Piepoli A, Panza A, Andriulli A, Resta N, Stella A. Identification and surveillance of 19 Lynch syndrome families in southern Italy: report of six novel germline mutations and a common founder mutation. Fam Cancer2011; 10: 285-295 [PMID: 21286823 DOI: 10.1007/s10689-011-9419-0]
25. 25 Zahary MN, Kaur G, Hassan MR, Sidek AS, Singh H, Yeh LY, Ankathil R. Germline mutation and protein expression analysis of mismatch repair genes MSH6 and PMS2 in Malaysian Lynch syndrome patients. Int J Colorectal Dis2014; 29: 261-262 [PMID: 24072394 DOI: 10.1007/s00384-013-1770-1]
26. 26 Cruz-Correa M, Diaz-Algorri Y, Pérez-Mayoral J, Suleiman-Suleiman W, Del Mar Gonzalez-Pons M, Bertrán C, Casellas N, Rodríguez N, Pardo S, Rivera K, Mosquera R, Rodriguez-Quilichini S. Clinical characterization and mutation spectrum in Caribbean Hispanic families with Lynch syndrome. Fam Cancer2015; 14: 415-425 [PMID: 25782445 DOI: 10.1007/s10689-015-9795-y]
27. 27 Bertagnolli MM, Niedzwiecki D, Compton CC, Hahn HP, Hall M, Damas B, Jewell SD, Mayer RJ, Goldberg RM, Saltz LB, Warren RS, Redston M. Microsatellite instability predicts improved response to adjuvant therapy with irinotecan, fluorouracil, and leucovorin in stage III colon cancer: Cancer and Leukemia Group B Protocol 89803. J Clin Oncol2009; 27: 1814-1821 [PMID: 19273709 DOI: 10.1200/JCO.2008.18.2071]
28. 28 Yamamoto H, Imai K. Microsatellite instability: an update. Arch Toxicol2015; 89: 899-921 [PMID: 25701956 DOI: 10.1007/s00204-015-1474-0]
29. 29 Woerner SM, Yuan YP, Benner A, Korff S, von Knebel Doeberitz M, Bork P. SelTarbase, a database of human mononucleotide-microsatellite mutations and their potential impact to tumorigenesis and immunology. Nucleic Acids Res2010; 38: D682-D689 [PMID: 19820113 DOI: 10.1093/nar/gkp839]
30. 30 Staffa L, Echterdiek F, Nelius N, Benner A, Werft W, Lahrmann B, Grabe N, Schneider M, Tariverdian M, von Knebel Doeberitz M, Bläker H, Kloor M. Mismatch repair-defcient crypt foci in Lynch syndrome–molecular alterations and association with clinical parameters. PLoS One2015; 10: e0121980 [PMID: 25816162 DOI: 10.1371/journal.pone.0121980]
31. 31 Tougeron D, Fauquembergue E, Rouquette A, Le Pessot F, Sesboüé R, Laurent M, Berthet P, Mauillon J, Di Fiore F, Sabourin JC, Michel P, Tosi M, Frébourg T, Latouche JB. Tumor-infiltrating lymphocytes in colorectal cancers with microsatellite instability are correlated with the number and spectrum of frameshift mutations. Mod Pathol2009; 22: 1186-1195 [PMID: 19503063 DOI: 10.1038/modpathol.2009.80]
32. 32 Schwitalle Y, Linnebacher M, Ripberger E, Gebert J, von Knebel Doeberitz M. Immunogenic peptides generated by frameshift mutations in DNA mismatch repair-defcient cancer cells. Cancer Immun2004; 4: 14 [PMID: 15563124]
33. 33 Kim TM, Laird PW, Park PJ. The landscape of microsatellite instability in colorectal and endometrial cancer genomes. Cell2013; 155: 858-868 [PMID: 24209623 DOI: 10.1016/j.cell.2013.10.015]
34. 34 Markowitz S, Wang J, Myeroff L, Parsons R, Sun L, Lutterbaugh J, Fan RS, Zborowska E, Kinzler KW, Vogelstein B. Inactivation of the type II TGF-beta receptor in colon cancer cells with microsatellite instability. Science1995; 268: 1336-1338 [PMID: 7761852]
35. 35 de Miranda NF, van Dinther M, van den Akker BE, van Wezel T, ten Dijke P, Morreau H. Transforming Growth Factor β Signaling in Colorectal Cancer Cells With Microsatellite Instability Despite Biallelic Mutations in TGFBR2. Gastroenterology2015; 148: 1427-1437.e8 [PMID: 25736321 DOI: 10.1053/j.gastro.2015.02.052]
36. 36 Peltomäki P. Epigenetic mechanisms in the pathogenesis of Lynch syndrome. Clin Genet2014; 85: 403-412 [PMID: 24443998 DOI: 10.1111/cge.12349]
37. 37 Ollikainen M, Hannelius U, Lindgren CM, Abdel-Rahman WM, Kere J, Peltomäki P. Mechanisms of inactivation of MLH1 in hereditary nonpolyposis colorectal carcinoma: a novel approach. Oncogene2007; 26: 4541-4549 [PMID: 17260015]
38. 38 Nagasaka T, Rhees J, Kloor M, Gebert J, Naomoto Y, Boland CR, Goel A. Somatic hypermethylation of MSH2 is a frequent event in Lynch Syndrome colorectal cancers. Cancer Res2010; 70: 3098-3108 [PMID: 20388775 DOI: 10.1158/0008-5472. CAN-09-3290]
39. 39 Gazzoli I, Loda M, Garber J, Syngal S, Kolodner RD. A hereditary nonpolyposis colorectal carcinoma case associated with hypermethylation of the MLH1 gene in normal tissue and loss of heterozygosity of the unmethylated allele in the resulting microsatellite instability-high tumor. Cancer Res2002; 62: 3925-3928 [PMID: 12124320]
40. 40 Miyakura Y, Sugano K, Akasu T, Yoshida T, Maekawa M, Saitoh S, Sasaki H, Nomizu T, Konishi F, Fujita S, Moriya Y, Nagai H. Extensive but hemiallelic methylation of the hMLH1 promoter region in early-onset sporadic colon cancers with microsatellite instability. Clin Gastroenterol Hepatol2004; 2: 147-156 [PMID: 15017620]
41. 41 Hitchins MP, Wong JJ, Suthers G, Suter CM, Martin DI, Hawkins NJ, Ward RL. Inheritance of a cancer-associated MLH1 germ-line epimutation. N Engl J Med2007; 356: 697-705 [PMID: 17301300]
42. 42 Chan TL, Yuen ST, Kong CK, Chan YW, Chan AS, Ng WF, Tsui WY, Lo MW, Tam WY, Li VS, Leung SY. Heritable germline epimutation of MSH2 in a family with hereditary nonpolyposis colorectal cancer. Nat Genet2006; 38: 1178-1183 [PMID: 16951683]
43. 43 Ligtenberg MJ, Kuiper RP, Chan TL, Goossens M, Hebeda KM, Voorendt M, Lee TY, Bodmer D, Hoenselaar E, Hendriks-Cornelissen SJ, Tsui WY, Kong CK, Brunner HG, van Kessel AG, Yuen ST, van Krieken JH, Leung SY, Hoogerbrugge N. Heritable somatic methylation and inactivation of MSH2 in families with Lynch syndrome due to deletion of the 3’ exons of TACSTD1. Nat Genet2009; 41: 112-117 [PMID: 19098912 DOI: 10.1038/ng.283]
44. 44 Kuiper RP, Vissers LE, Venkatachalam R, Bodmer D, Hoenselaar E, Goossens M, Haufe A, Kamping E, Niessen RC, Hogervorst FB, Gille JJ, Redeker B, Tops CM, van Gijn ME, van den Ouweland AM, Rahner N, Steinke V, Kahl P, Holinski-Feder E, Morak M, Kloor M, Stemmler S, Betz B, Hutter P, Bunyan DJ, Syngal S, Culver JO, Graham T, Chan TL, Nagtegaal ID, van Krieken JH, Schackert HK, Hoogerbrugge N, van Kessel AG, Ligtenberg MJ. Recurrence and variability of germline EPCAM deletions in Lynch syndrome. Hum Mutat2011; 32: 407-414 [PMID: 21309036 DOI: 10.1002/humu.21446]
45. 45 Hutchison J, Cohen Z, Onyeagucha BC, Funk J, Nelson MA. How microRNAs infuence both hereditary and infammatory-mediated colon cancers. Cancer Genet2013; 206: 309-316 [PMID: 24042167 DOI: 10.1016/j.cancergen.2013.06.005]
46. 46 Valeri N, Gasparini P, Fabbri M, Braconi C, Veronese A, Lovat F, Adair B, Vannini I, Fanini F, Bottoni A, Costinean S, Sandhu SK, Nuovo GJ, Alder H, Gafa R, Calore F, Ferracin M, Lanza G, Volinia S, Negrini M, McIlhatton MA, Amadori D, Fishel R, Croce CM. Modulation of mismatch repair and genomic stability by miR-155. Proc Natl Acad Sci USA2010; 107: 6982-6987 [PMID: 20351277 DOI: 10.1073/pnas.1002472107]
47. 47 Balaguer F, Moreira L, Lozano JJ, Link A, Ramirez G, Shen Y, Cuatrecasas M, Arnold M, Meltzer SJ, Syngal S, Stoffel E, Jover R, Llor X, Castells A, Boland CR, Gironella M, Goel A. Colorectal cancers with microsatellite instability display unique miRNA profles. Clin Cancer Res2011; 17: 6239-6249 [PMID: 21844009 DOI: 10.1158/1078-0432.CCR-11-1424]
48. 48 Earle JS, Luthra R, Romans A, Abraham R, Ensor J, Yao H, Hamilton SR. Association of microRNA expression with microsatellite instability status in colorectal adenocarcinoma. J Mol Diagn2010; 12: 433-440 [PMID: 20413677 DOI: 10.2353/jmoldx.2010.090154]
49. 49 Kaur S, Lotsari JE, Al-Sohaily S, Warusavitarne J, Kohonen-Corish MR, Peltomäki P. Identification of subgroup-specific miRNA patterns by epigenetic profling of sporadic and Lynch syndrome-associated colorectal and endometrial carcinoma. Clin Epigenetics2015; 7: 20 [PMID: 25767621 DOI: 10.1186/s13148-015-0059-3]
50. 50 Ozsolak F, Poling LL, Wang Z, Liu H, Liu XS, Roeder RG, Zhang X, Song JS, Fisher DE. Chromatin structure analyses identify miRNA promoters. Genes Dev2008; 22: 3172-3183 [PMID: 19056895 DOI: 10.1101/gad.1706508]
51. 51 Lindor NM, Rabe K, Petersen GM, Haile R, Casey G, Baron J, Gallinger S, Bapat B, Aronson M, Hopper J, Jass J, LeMarchand L, Grove J, Potter J, Newcomb P, Terdiman JP, Conrad P, Moslein G, Goldberg R, Ziogas A, Anton-Culver H, de Andrade M, Siegmund K, Thibodeau SN, Boardman LA, Seminara D. Lower cancer incidence in Amsterdam-I criteria families without mismatch repair deficiency: familial colorectal cancer type X. JAMA2005; 293: 1979-1985 [PMID: 15855431]
52. 52 Klarskov L, Holck S, Bernstein I, Nilbert M. Hereditary colorectal cancer diagnostics: morphological features of familial colorectal cancer type X versus Lynch syndrome. J Clin Pathol2012; 65: 352-356 [PMID: 22287689 DOI: 10.1136/jclinpath-2011-200535]
53. 53 Sánchez-Tomé E, Rivera B, Perea J, Pita G, Rueda D, Mercadillo F, Canal A, Gonzalez-Neira A, Benitez J, Urioste M. Genome-wide linkage analysis and tumoral characterization reveal heterogeneity in familial colorectal cancer type X. J Gastroenterol2015; 50: 657-666 [PMID: 25381643 DOI: 10.1007/s00535-014-1009-0]
54. 54 Dunican DS, McWilliam P, Tighe O, Parle-McDermott A, Croke DT. Gene expression differences between the microsatellite instability (MIN) and chromosomal instability (CIN) phenotypes in colorectal cancer revealed by high-density cDNA array hybridization. Oncogene2002; 21: 3253-3257 [PMID: 12082642]
55. 55 Bertucci F, Salas S, Eysteries S, Nasser V, Finetti P, Ginestier C, Charafe-Jauffret E, Loriod B, Bachelart L, Montfort J, Victorero G, Viret F, Ollendorff V, Fert V, Giovaninni M, Delpero JR, Nguyen C, Viens P, Monges G, Birnbaum D, Houlgatte R. Gene expression profling of colon cancer by DNA microarrays and correlation with histoclinical parameters. Oncogene2004; 23: 1377-1391 [PMID: 14973550]
56. 56 Francisco I, Albuquerque C, Lage P, Belo H, Vitoriano I, Filipe B, Claro I, Ferreira S, Rodrigues P, Chaves P, Leitão CN, Pereira AD. Familial colorectal cancer type X syndrome: two distinct molecular entities? Fam Cancer2011; 10: 623-631 [PMID: 21837511 DOI: 10.1007/s10689-011-9473-7]
57. 57 Therkildsen C, Jönsson G, Dominguez-Valentin M, Nissen A, Rambech E, Halvarsson B, Bernstein I, Borg K, Nilbert M. Gain of chromosomal region 20q and loss of 18 discriminates between Lynch syndrome and familial colorectal cancer. Eur J Cancer2013; 49: 1226-1235 [PMID: 23245329 DOI: 10.1016/j.ejca.2012.11.011]
58. 58 Dominguez-Valentin M, Therkildsen C, Veerla S, Jönsson M, Bernstein I, Borg A, Nilbert M. Distinct gene expression signatures in lynch syndrome and familial colorectal cancer type x. PLoS One2013; 8: e71755 [PMID: 23951239 DOI: 10.1371/journal. pone.0071755]
59. 59 Watanabe K, Kawamori T, Nakatsugi S, Ohta T, Ohuchida S, Yamamoto H, Maruyama T, Kondo K, Ushikubi F, Narumiya S, Sugimura T, Wakabayashi K. Role of the prostaglandin E receptor subtype EP1 in colon carcinogenesis. Cancer Res1999; 59: 5093-5096 [PMID: 10537280]
60. 60 Kim SH, Park YY, Kim SW, Lee JS, Wang D, DuBois RN. ANGPTL4 induction by prostaglandin E2 under hypoxic conditions promotes colorectal cancer progression. Cancer Res2011; 71: 7010-7020 [PMID: 21937683 DOI: 10.1158/0008-5472. CAN-11-1262]
61. 61 Schulz E, Klampf P, Holzapfel S, Janecke AR, Ulz P, Renner W, Kashofer K, Nojima S, Leitner A, Zebisch A, Wölfer A, Hofer S, Gerger A, Lax S, Beham-Schmid C, Steinke V, Heitzer E, Geigl JB, Windpassinger C, Hoefler G, Speicher MR, Boland CR, Kumanogoh A, Sill H. Germline variants in the SEMA4A gene predispose to familial colorectal cancer type X. Nat Commun2014; 5: 5191 [PMID: 25307848 DOI: 10.1038/ncomms6191]
62. 62 Jarry J, Brunet JS, Laframboise R, Drouin R, Latreille J, Richard C, Gekas J, Maranda B, Monczak Y, Wong N, Pouchet C, Zaor S, Kasprzak L, Palma L, Wu MK, Tischkowitz M, Foulkes WD, Chong G. A survey of APC mutations in Quebec. Fam Cancer2011; 10: 659-665 [PMID: 21779980 DOI: 10.1007/s10689-011-9468-4]
63. 63 Kinzler KW, Nilbert MC, Su LK, Vogelstein B, Bryan TM, Levy DB, Smith KJ, Preisinger AC, Hedge P, McKechnie D. Identifcation of FAP locus genes from chromosome 5q21. Science1991; 253: 661-665 [PMID: 1651562]
64. 64 Polakis P. Casein kinase 1: a Wnt’er of disconnect. Curr Biol2002; 12: R499-R501 [PMID: 12176352]
65. 65 Fodde R, Kuipers J, Rosenberg C, Smits R, Kielman M, Gaspar C, van Es JH, Breukel C, Wiegant J, Giles RH, Clevers H. Mutations in the APC tumour suppressor gene cause chromosomal instability. Nat Cell Biol2001; 3: 433-438 [PMID: 11283620]
66. 66 Kaplan KB, Burds AA, Swedlow JR, Bekir SS, Sorger PK, Näthke IS. A role for the Adenomatous Polyposis Coli protein in chromosome segregation. Nat Cell Biol2001; 3: 429-432 [PMID: 11283619]
67. 67 Rozen P, Macrae F. Familial adenomatous polyposis: The practical applications of clinical and molecular screening. Fam Cancer2006; 5: 227-235 [PMID: 16998668]
68. 68 Schlussel AT, Gagliano RA, Seto-Donlon S, Eggerding F, Donlon T, Berenberg J, Lynch HT. The evolution of colorectal cancer genetics-Part 2: clinical implications and applications. J Gastrointest Oncol2014; 5: 336-344 [PMID: 25276406 DOI: 10.3978/j.issn.2078-6891.2014.068]
69. 69 Béroud C, Soussi T. APC gene: database of germline and somatic mutations in human tumors and cell lines. Nucleic Acids Res1996; 24: 121-124 [PMID: 8594558]
70. 70 Martayan A, Sanchez-Mete L, Baldelli R, Falvo E, Barnabei A, Conti L, Giacomini P, Appetecchia M, Stigliano V. Gene variants associated to malignant thyroid disease in familial adenomatous polyposis: a novel APC germline mutation. J Endocrinol Invest2010; 33: 603-606 [PMID: 20935450 DOI: 10.3275/7289]
71. 71 Hamilton SR, Liu B, Parsons RE, Papadopoulos N, Jen J, Powell SM, Krush AJ, Berk T, Cohen Z, Tetu B. The molecular basis of Turcot’s syndrome. N Engl J Med1995; 332: 839-847 [PMID: 7661930]
72. 72 Groen EJ, Roos A, Muntinghe FL, Enting RH, de Vries J, Kleibeuker JH, Witjes MJ, Links TP, van Beek AP. Extra-intestinal manifestations of familial adenomatous polyposis. Ann Surg Oncol2008; 15: 2439-2450 [PMID: 18612695 DOI: 10.1245/s10434-008-9981-3]
73. 73 Septer S, Slowik V, Morgan R, Dai H, Attard T. Thyroid cancer complicating familial adenomatous polyposis: mutation spectrum of at-risk individuals. Hered Cancer Clin Pract2013; 11: 13 [PMID: 24093640 DOI: 10.1186/1897-4287-11-13]
74. 74 Lamberti C, Jungck M, Laarmann M, Knapp M, Caspari R, Friedl W, Sauerbruch T, Propping P, Kruse R. Arylamine N-acetyltransferase type 2 and glutathione S-transferases M1 and T1 polymorphisms in familial adenomatous polyposis. Pharmacogenetics2002; 12: 49-54 [PMID: 11773864]
75. 75 Hashimoto T, Ogawa R, Matsubara A, Taniguchi H, Sugano K, Ushiama M, Yoshida T, Kanai Y, Sekine S. Familial adenomatous polyposis-associated and sporadic pyloric gland adenomas of the upper gastrointestinal tract share common genetic features. Histopathology2015; 67: 689-698 [PMID: 25832318 DOI: 10.1111/his.12705]
76. 76 Janssen KP, Alberici P, Fsihi H, Gaspar C, Breukel C, Franken P, Rosty C, Abal M, El Marjou F, Smits R, Louvard D, Fodde R, Robine S. APC and oncogenic KRAS are synergistic in enhancing Wnt signaling in intestinal tumor formation and progression. Gastroenterology2006; 131: 1096-1109 [PMID: 17030180]
77. 77 Haigis KM, Kendall KR, Wang Y, Cheung A, Haigis MC, Glickman JN, Niwa-Kawakita M, Sweet-Cordero A, Sebolt-Leopold J, Shannon KM, Settleman J, Giovannini M, Jacks T. Differential effects of oncogenic K-Ras and N-Ras on proliferation, differentiation and tumor progression in the colon. Nat Genet2008; 40: 600-608 [PMID: 18372904 DOI: 10.1038/ng.115]
78. 78 Phelps RA, Chidester S, Dehghanizadeh S, Phelps J, Sandoval IT, Rai K, Broadbent T, Sarkar S, Burt RW, Jones DA. A two-step model for colon adenoma initiation and progression caused by APC loss. Cell2009; 137: 623-634 [PMID: 19450512 DOI: 10.1016/j.cell.2009.02.037]
79. 79 Obrador-Hevia A, Chin SF, González S, Rees J, Vilardell F, Greenson JK, Cordero D, Moreno V, Caldas C, Capellá G. Onco-genic KRAS is not necessary for Wnt signalling activation in APC-associated FAP adenomas. J Pathol2010; 221: 57-67 [PMID: 20196079 DOI: 10.1002/path.2685]
80. 80 Romero-Giménez J, Dopeso H, Blanco I, Guerra-Moreno A, Gonzalez S, Vogt S, Aretz S, Schwartz S, Capella G, Arango D. Germline hypermethylation of the APC promoter is not a frequent cause of familial adenomatous polyposis in APC/MUTYH mutation negative families. Int J Cancer2008; 122: 1422-1425 [PMID: 18027849]
81. 81 Kámory E, Olasz J, Csuka O. Somatic APC inactivation mechanisms in sporadic colorectal cancer cases in Hungary. Pathol Oncol Res2008; 14: 51-56 [PMID: 18369740 DOI: 10.1007/s1225 3-008-9019-y]
82. 82 Zhang YY, Chen SQ, Zhu M, Li JT, Ma GJ, Zhang XM, Zhou JN. [Promoter hypermethylation and loss of heterozygosity of the APC gene in patients with familial adenomatous polyposis]. Zhonghua Yi Xue Yi Chuan Xue Za Zhi2008; 25: 378-381 [PMID: 18683131]
83. 83 Segditsas S, Sieber OM, Rowan A, Setien F, Neale K, Phillips RK, Ward R, Esteller M, Tomlinson IP. Promoter hypermethylation leads to decreased APC mRNA expression in familial polyposis and sporadic colorectal tumours, but does not substitute for truncating mutations. Exp Mol Pathol2008; 85: 201-206 [PMID: 18977219 DOI: 10.1016/j.yexmp.2008.09.006]
84. 84 Pavicic W, Nieminen TT, Gylling A, Pursiheimo JP, Laiho A, Gyenesei A, Järvinen HJ, Peltomäki P. Promoter-specifc alterations of APC are a rare cause for mutation-negative familial adenomatous polyposis. Genes Chromosomes Cancer2014; 53: 857-864 [PMID: 24946964 DOI: 10.1002/gcc.22197]
85. 85 Berkhout M, Nagtegaal ID, Cornelissen SJ, Dekkers MM, van de Molengraft FJ, Peters WH, Nagengast FM, van Krieken JH, Jeuken JW. Chromosomal and methylation alterations in sporadic and familial adenomatous polyposis-related duodenal carcinomas. Mod Pathol2007; 20: 1253-1262 [PMID: 17873900]
86. 86 Wynter CV, Kambara T, Walsh MD, Leggett BA, Young J, Jass JR. DNA methylation patterns in adenomas from FAP, multiple adenoma and sporadic colorectal carcinoma patients. Int J Cancer2006; 118: 907-915 [PMID: 16152625]
87. 87 Kamatani A, Nakagawa Y, Akao Y, Maruyama N, Nagasaka M, Shibata T, Tahara T, Hirata I. Downregulation of anti-oncomirs miR-143/145 cluster occurs before APC gene aberration in the development of colorectal tumors. Med Mol Morphol2013; 46: 166-171 [PMID: 23397547 DOI: 10.1007/s00795-013-0020-5]
88. 88 Yamaguchi T, Iijima T, Wakaume R, Takahashi K, Matsumoto H, Nakano D, Nakayama Y, Mori T, Horiguchi S, Miyaki M. Underexpression of miR-126 and miR-20b in hereditary and nonhereditary colorectal tumors. Oncology2014; 87: 58-66 [PMID: 24994098 DOI: 10.1159/000363303]
89. 89 Croitoru ME, Cleary SP, Di Nicola N, Manno M, Selander T, Aronson M, Redston M, Cotterchio M, Knight J, Gryfe R, Gallinger S. Association between biallelic and monoallelic germline MYH gene mutations and colorectal cancer risk. J Natl Cancer Inst2004; 96: 1631-1634 [PMID: 15523092]
90. 90 Lubbe SJ, Di Bernardo MC, Chandler IP, Houlston RS. Clinical implications of the colorectal cancer risk associated with MUTYH mutation. J Clin Oncol2009; 27: 3975-3980 [PMID: 19620482 DOI: 10.1200/JCO.2008.21.6853]
91. 91 Church J, Heald B, Burke C, Kalady M. Understanding MYH-associated neoplasia. Dis Colon Rectum2012; 55: 359-362 [PMID: 22469805 DOI: 10.1097/DCR.0b013e31823a9392]
92. 92 Yamaguchi S, Ogata H, Katsumata D, Nakajima M, Fujii T, Tsutsumi S, Asao T, Sasaki K, Kuwano H, Kato H. MUTYH-associated colorectal cancer and adenomatous polyposis. Surg Today2014; 44: 593-600 [PMID: 23605219 DOI: 10.1007/s00595-013-0592-7]
93. 93 Farrington SM, Tenesa A, Barnetson R, Wiltshire A, Prendergast J, Porteous M, Campbell H, Dunlop MG. Germline susceptibility to colorectal cancer due to base-excision repair gene defects. Am J Hum Genet2005; 77: 112-119 [PMID: 15931596]
94. 94 Al-Tassan N, Chmiel NH, Maynard J, Fleming N, Livingston AL, Williams GT, Hodges AK, Davies DR, David SS, Sampson JR, Cheadle JP. Inherited variants of MYH associated with somatic G: C–> T: A mutations in colorectal tumors. Nat Genet2002; 30: 227-232 [PMID: 11818965]
95. 95 Knudson AG. Hereditary cancers: from discovery to intervention. J Natl Cancer Inst Monogr1995; (17): 5-7 [PMID: 8573454]
96. 96 Jones S, Emmerson P, Maynard J, Best JM, Jordan S, Williams GT, Sampson JR, Cheadle JP. Biallelic germline mutations in MYH predispose to multiple colorectal adenoma and somatic G: C–> T: A mutations. Hum Mol Genet2002; 11: 2961-2967 [PMID: 12393807]
97. 97 Sieber OM, Lipton L, Crabtree M, Heinimann K, Fidalgo P, Phillips RK, Bisgaard ML, Orntoft TF, Aaltonen LA, Hodgson SV, Thomas HJ, Tomlinson IP. Multiple colorectal adenomas, classic adenomatous polyposis, and germ-line mutations in MYH. N Engl J Med2003; 348: 791-799 [PMID: 12606733]
98. 98 Nielsen M, Joerink-van de Beld MC, Jones N, Vogt S, Tops CM, Vasen HF, Sampson JR, Aretz S, Hes FJ. Analysis of MUTYH genotypes and colorectal phenotypes in patients With MUTYH-associated polyposis. Gastroenterology2009; 136: 471-476 [PMID: 19032956 DOI: 10.1053/j.gastro.2008.10.056]
99. 99 Miyaki M, Iijima T, Yamaguchi T, Hishima T, Tamura K, Utsunomiya J, Mori T. Germline mutations of the MYH gene in Japanese patients with multiple colorectal adenomas. Mutat Res2005; 578: 430-433 [PMID: 15890374]
100. 100 Alhopuro P, Parker AR, Lehtonen R, Enholm S, Järvinen HJ, Mecklin JP, Karhu A, Eshleman JR, Aaltonen LA. A novel functionally defcient MYH variant in individuals with colorectal adenomatous polyposis. Hum Mutat2005; 26: 393 [PMID: 16134146]
101. 101 Pin E, Pastrello C, Tricarico R, Papi L, Quaia M, Fornasarig M, Carnevali I, Oliani C, Fornasin A, Agostini M, Maestro R, Barana D, Aretz S, Genuardi M, Viel A. MUTYH c.933+3A& gt; C, associated with a severely impaired gene expression, is the first Italian founder mutation in MUTYH-Associated Polyposis. Int J Cancer2013; 132: 1060-1069 [PMID: 22865608 DOI: 10.1002/ijc.27761]
102. 102 Venesio T, Balsamo A, Errichiello E, Ranzani GN, Risio M. Oxidative DNA damage drives carcinogenesis in MUTYH-associated-polyposis by specific mutations of mitochondrial and MAPK genes. Mod Pathol2013; 26: 1371-1381 [PMID: 23599153 DOI: 10.1038/modpathol.2013.66]
103. 103 Cichy W, Klincewicz B, Plawski A. Juvenile polyposis syndrome. Arch Med Sci2014; 10: 570-577 [PMID: 25097590 DOI: 10.5114/aoms.2014.43750]
104. 104 Gallione CJ, Repetto GM, Legius E, Rustgi AK, Schelley SL, Tejpar S, Mitchell G, Drouin E, Westermann CJ, Marchuk DA. A combined syndrome of juvenile polyposis and hereditary haemorrhagic telangiectasia associated with mutations in MADH4 (SMAD4). Lancet2004; 363: 852-859 [PMID: 15031030]
105. 105 Brosens LA, Langeveld D, van Hattem WA, Giardiello FM, Offerhaus GJ. Juvenile polyposis syndrome. World J Gastroenterol2011; 17: 4839-4844 [PMID: 22171123 DOI: 10.3748/wjg.v17. i44.4839]
106. 106 Howe JR, Shellnut J, Wagner B, Ringold JC, Sayed MG, Ahmed AF, Lynch PM, Amos CI, Sistonen P, Aaltonen LA. Common deletion of SMAD4 in juvenile polyposis is a mutational hotspot. Am J Hum Genet2002; 70: 1357-1362 [PMID: 11920286]
107. 107 Yamaguchi J, Nagayama S, Chino A, Sakata A, Yamamoto N, Sato Y, Ashihara Y, Kita M, Nomura S, Ishikawa Y, Igarashi M, Ueno M, Arai M. Identifcation of coding exon 3 duplication in the BMPR1A gene in a patient with juvenile polyposis syndrome. Jpn J Clin Oncol2014; 44: 1004-1008 [PMID: 25129392 DOI: 10.1093/jjco/hyu111]
108. 108 Woodford-Richens K, Bevan S, Churchman M, Dowling B, Jones D, Norbury CG, Hodgson SV, Desai D, Neale K, Phillips RK, Young J, Leggett B, Dunlop M, Rozen P, Eng C, Markie D, Rodriguez-Bigas MA, Sheridan E, Iwama T, Eccles D, Smith GT, Kim JC, Kim KM, Sampson JR, Evans G, Tejpar S, Bodmer WF, Tomlinson IP, Houlston RS. Analysis of genetic and phenotypic heterogeneity in juvenile polyposis. Gut2000; 46: 656-660 [PMID: 10764709]
109. 109 Woodford-Richens KL, Rowan AJ, Poulsom R, Bevan S, Salovaara R, Aaltonen LA, Houlston RS, Wright NA, Tomlinson IP. Comprehensive analysis of SMAD4 mutations and protein expression in juvenile polyposis: evidence for a distinct genetic pathway and polyp morphology in SMAD4 mutation carriers. Am J Pathol2001; 159: 1293-1300 [PMID: 11583957]
110. 110 Marsh DJ, Roth S, Lunetta KL, Hemminki A, Dahia PL, Sistonen P, Zheng Z, Caron S, van Orsouw NJ, Bodmer WF, Cottrell SE, Dunlop MG, Eccles D, Hodgson SV, Järvinen H, Kellokumpu I, Markie D, Neale K, Phillips R, Rozen P, Syngal S, Vijg J, Tomlinson IP, Aaltonen LA, Eng C. Exclusion of PTEN and 10q22-24 as the susceptibility locus for juvenile polyposis syndrome. Cancer Res1997; 57: 5017-5021 [PMID: 9371495]
111. 111 Ling H, Pickard K, Ivan C, Isella C, Ikuo M, Mitter R, Spizzo R, Bullock MD, Braicu C, Pileczki V, Vincent K, Pichler M, Stiegelbauer V, Hoefler G, Almeida MI, Hsiao A, Zhang X, Primrose JN, Packham GK, Liu K, Bojja K, Gafà R, Xiao L, Rossi S, Song JH, Vannini I, Fanini F, Kopetz S, Zweidler-McKay P, Wang X, Ionescu C, Irimie A, Fabbri M, Lanza G, Hamilton SR, Berindan-Neagoe I, Medico E, Mirnezami AH, Calin GA, Nicoloso MS. The clinical and biological signifcance of MIR-224 expression in colorectal cancer metastasis. Gut2015; Epub ahead of print [PMID: 25804630 DOI: 10.1136/gutjnl-2015-309372]
112. 112 Jenne DE, Reimann H, Nezu J, Friedel W, Loff S, Jeschke R, Müller O, Back W, Zimmer M. Peutz-Jeghers syndrome is caused by mutations in a novel serine threonine kinase. Nat Genet1998; 18: 38-43 [PMID: 9425897]
113. 113 Schreibman IR, Baker M, Amos C, McGarrity TJ. The hamartomatous polyposis syndromes: a clinical and molecular review. Am J Gastroenterol2005; 100: 476-490 [PMID: 15667510]
114. 114 Tomas C, Soyer P, Dohan A, Dray X, Boudiaf M, Hoeffel C. Update on imaging of Peutz-Jeghers syndrome. World J Gastroenterol2014; 20: 10864-10875 [PMID: 25152588 DOI: 10.3748/wjg.v20.i31]
115. 115 Giardiello FM, Trimbath JD. Peutz-Jeghers syndrome and management recommendations. Clin Gastroenterol Hepatol2006; 4: 408-415 [PMID: 16616343]
116. 116 Giardiello FM, Brensinger JD, Tersmette AC, Goodman SN, Petersen GM, Booker S V, Cruz-Correa M, Offerhaus JA. Very high risk of cancer in familial Peutz-Jeghers syndrome. Gastroenterology2000; 119: 1447-1453 [PMID: 11113065]
117. 117 van Lier MG, Westerman AM, Wagner A, Looman CW, Wilson JH, de Rooij FW, Lemmens VE, Kuipers EJ, Mathus-Vliegen EM, van Leerdam ME. High cancer risk and increased mortality in patients with Peutz-Jeghers syndrome. Gut2011; 60: 141-147 [PMID: 21205875 DOI: 10.1136/gut.2010.223750]
118. 118 Kopacova M, Tacheci I, Rejchrt S, Bures J. Peutz-Jeghers syndrome: diagnostic and therapeutic approach. World J Gastroenterol2009; 15: 5397-5408 [PMID: 19916169]
119. 119 Rossi DJ, Ylikorkala A, Korsisaari N, Salovaara R, Luukko K, Launonen V, Henkemeyer M, Ristimaki A, Aaltonen LA, Makela TP. Induction of cyclooxygenase-2 in a mouse model of Peutz-Jeghers polyposis. Proc Natl Acad Sci USA2002; 99: 12327-12332 [PMID: 12218179]
120. 120 Takeda H, Miyoshi H, Tamai Y, Oshima M, Taketo MM. Simultaneous expression of COX-2 and mPGES-1 in mouse gastrointestinal hamartomas. Br J Cancer2004; 90: 701-704 [PMID: 14760387]
121. 121 Wang HH, Xie NN, Li QY, Hu YQ, Ren JL, Guleng B. Exome sequencing revealed novel germline mutations in Chinese Peutz-Jeghers syndrome patients. Dig Dis Sci2014; 59: 64-71 [PMID: 24154639 DOI: 10.1007/s10620-013-2875-7]
122. 122 Mehenni H, Blouin JL, Radhakrishna U, Bhardwaj SS, Bhardwaj K, Dixit VB, Richards KF, Bermejo-Fenoll A, Leal AS, Raval RC, Antonarakis SE. Peutz-Jeghers syndrome: confrmation of linkage to chromosome 19p13.3 and identification of a potential second locus, on 19q13.4. Am J Hum Genet1997; 61: 1327-1334 [PMID: 9399902]
123. 123 Amos CI, Bali D, Thiel TJ, Anderson JP, Gourley I, Frazier ML, Lynch PM, Luchtefeld MA, Young A, McGarrity TJ, Seldin MF. Fine mapping of a genetic locus for Peutz-Jeghers syndrome on chromosome 19p. Cancer Res1997; 57: 3653-3656 [PMID: 9288765]
124. 124 Markie D, Huson S, Maher E, Davies A, Tomlinson I, Bodmer WF. A pericentric inversion of chromosome six in a patient with Peutz-Jeghers’ syndrome and the use of FISH to localise the breakpoints on a genetic map. Hum Genet1996; 98: 125-128 [PMID: 8698325]
125. 125 Alhopuro P, Phichith D, Tuupanen S, Sammalkorpi H, Nybondas M, Saharinen J, Robinson JP, Yang Z, Chen LQ, Orntoft T, Mecklin JP, Järvinen H, Eng C, Moeslein G, Shibata D, Houlston RS, Lucassen A, Tomlinson IP, Launonen V, Ristimäki A, Arango D, Karhu A, Sweeney HL, Aaltonen LA. Unregulated smooth-muscle myosin in human intestinal neoplasia. Proc Natl Acad Sci USA2008; 105: 5513-5518 [PMID: 18391202 DOI: 10.1073/pnas.0801213105]
126. 126 Launonen V. Mutations in the human LKB1/STK11 gene. Hum Mutat2005; 26: 291-297 [PMID: 16110486]
127. 127 Dong SM, Kim KM, Kim SY, Shin MS, Na EY, Lee SH, Park WS, Yoo NJ, Jang JJ, Yoon CY, Kim JW, Kim SY, Yang YM, Kim SH, Kim CS, Lee JY. Frequent somatic mutations in serine/threonine kinase 11/Peutz-Jeghers syndrome gene in left-sided colon cancer. Cancer Res1998; 58:3787-3790 [PMID: 9731485]
128. 128 Resta N, Simone C, Mareni C, Montera M, Gentile M, Susca F, Gristina R, Pozzi S, Bertario L, Bufo P, Carlomagno N, Ingrosso M, Rossini FP, Tenconi R, Guanti G. STK11 mutations in Peutz-Jeghers syndrome and sporadic colon cancer. Cancer Res1998; 58: 4799-4801 [PMID: 9809980]
129. 129 Bartosova Z, Zavodna K, Krivulcik T, Usak J, Mlkva I, Kruzliak T, Hromec J, Usakova V, Kopecka I, Veres P, Bartosova Z, Bujalkova M. STK11/LKB1 germline mutations in the first Peutz-Jeghers syndrome patients identified in Slovakia. Neoplasma2007; 54: 101-107 [PMID: 17319781]
130. 130 Esteller M, Avizienyte E, Corn PG, Lothe RA, Baylin SB, Aaltonen LA, Herman JG. Epigenetic inactivation of LKB1 in primary tumors associated with the Peutz-Jeghers syndrome. Oncogene2000; 19: 164-168 [PMID: 10644993]
131. 131 Miyoshi H, Nakau M, Ishikawa TO, Seldin MF, Oshima M, Taketo MM. Gastrointestinal hamartomatous polyposis in Lkb1 heterozygous knockout mice. Cancer Res2002; 62: 2261-2266 [PMID: 11956081]
132. 132 Bardeesy N, Sinha M, Hezel AF, Signoretti S, Hathaway NA, Sharpless NE, Loda M, Carrasco DR, DePinho RA. Loss of the Lkb1 tumour suppressor provokes intestinal polyposis but resistance to transformation. Nature2002; 419: 162-167 [PMID: 12226664]
133. 133 Hosogi H, Nagayama S, Kawamura J, Koshiba Y, Nomura A, Itami A, Okabe H, Satoh S, Watanabe G, Sakai Y. Molecular insights into Peutz-Jeghers syndrome: two probands with a germline mutation of LKB1. J Gastroenterol2008; 43: 492-497 [PMID: 18600394 DOI: 10.1007/s00535-008-2185-6]
134. 134 Lynch HT, de la Chapelle A. Hereditary colorectal cancer. N Engl J Med2003; 348: 919-932 [PMID: 12621137]
135. 135 Samowitz WS, Curtin K, Lin HH, Robertson MA, Schaffer D, Nichols M, Gruenthal K, Leppert MF, Slattery ML. The colon cancer burden of genetically defned hereditary nonpolyposis colon cancer. Gastroenterology2001; 121: 830-838 [PMID: 11606497]
136. 136 Herman JG, Umar A, Polyak K, Graff JR, Ahuja N, Issa JP, Markowitz S, Willson JK, Hamilton SR, Kinzler KW, Kane MF, Kolodner RD, Vogelstein B, Kunkel TA, Baylin SB. Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma. Proc Natl Acad Sci USA1998; 95: 6870-6875 [PMID: 9618505]
137. 137 Kirzin S, Marisa L, Guimbaud R, De Reynies A, Legrain M, Laurent-Puig P, Cordelier P, Pradère B, Bonnet D, Meggetto F, Portier G, Brousset P, Selves J. Sporadic early-onset colorectal cancer is a specifc sub-type of cancer: a morphological, molecular and genetics study. PLoS One2014; 9: e103159 [PMID: 25083765 DOI: 10.1371/journal.pone.0103159]
138. 138 Boland CR, Goel A. Microsatellite instability in colorectal cancer. Gastroenterology2010; 138: 2073-2087.e3 [PMID: 20420947 DOI: 10.1053/j.gastro.2009.12.064]
139. 139 Walther A, Johnstone E, Swanton C, Midgley R, Tomlinson I, Kerr D. Genetic prognostic and predictive markers in colorectal cancer. Nat Rev Cancer2009; 9: 489-499 [PMID: 19536109 DOI: 10.1038/nrc2645]
140. 140 Cai G, Xu Y, Lu H, Shi Y, Lian P, Peng J, Du X, Zhou X, Guan Z, Shi D, Cai S. Clinicopathologic and molecular features of sporadic microsatelliteand chromosomal-stable colorectal cancers. Int J Colorectal Dis2008; 23: 365-373 [PMID: 18193434 DOI: 10.1007/s00384-007-0423-7]
141. 141 Silver A, Sengupta N, Propper D, Wilson P, Hagemann T, Patel A, Parker A, Ghosh A, Feakins R, Dorudi S, Suraweera N. A distinct DNA methylation profle associated with microsatellite and chromosomal stable sporadic colorectal cancers. Int J Cancer2012; 130: 1082-1092 [PMID: 21455990 DOI: 10.1002/ijc.26104]
142. 142 Hill DA, Furman WL, Billups CA, Riedley SE, Cain AM, Rao BN, Pratt CB, Spunt SL. Colorectal carcinoma in childhood and adolescence: a clinicopathologic review. J Clin Oncol2007; 25: 5808-5814 [PMID: 18089879]
143. 143 Lanza G, Ferracin M, Gafà R, Veronese A, Spizzo R, Pichiorri F, Liu CG, Calin GA, Ctabel 6roce CM, Negrini M. mRNA/microRNA gene expression profile in microsatellite unstable colorectal cancer. Mol Cancer2007; 6: 54 [PMID: 17716371 DOI: 10.1186/1476-4598-6-54]
144. 144 Yamamoto H, Adachi Y, Taniguchi H, Kunimoto H, Nosho K, Suzuki H, Shinomura Y. Interrelationship between microsatellite instability and microRNA in gastrointestinal cancer. World J Gastroenterol2012; 18: 2745-2755 [PMID: 22719182 DOI: 10.3748/wjg.v18.i22.2745]
145. 145 Fernandez-Rozadilla C, Brea-Fernández A, Bessa X, Alvarez-Urturi C, Abulí A, Clofent J, Payá A, Jover R, Xicola R, Llor X, Andreu M, Castells A, Carracedo A, Castellví-Bel S, Ruiz-Ponte C. BMPR1A mutations in early-onset colorectal cancer with mismatch repair profciency. Clin Genet2013; 84: 94-96 [PMID: 23057600 DOI: 10.1111/cge.12023]
146. 146 Luo T, Wu S, Shen X, Li L. Network cluster analysis of protein-protein interaction network identified biomarker for early onset colorectal cancer. Mol Biol Rep2013; 40: 6561-6568 [PMID: 24197691 DOI: 10.1007/s11033-013-2694-0]
147. 147 Ak S, Tunca B, Yilmazlar T, Tezcan G, Cecener G, Egeli U, Ozturk E, Yerci O, Ertürk E, Zorluoglu A. Microsatellite instability status affects gene expression profiles in early onset colorectal cancer patients. J Surg Res2013; 185: 626-637 [PMID: 23992855 DOI: 10.1016/j.jss.2013.07.014]
148. 148 Moll R, Löwe A, Laufer J, Franke WW. Cytokeratin 20 in human carcinomas. A new histodiagnostic marker detected by monoclonal antibodies. Am J Pathol1992; 140: 427-447 [PMID: 1371204]
149. 149 Tunca B, Tezcan G, Cecener G, Egeli U, Zorluoglu A, Yilmazlar T, Ak S, Yerci O, Ozturk E, Umut G, Evrensel T. Overexpression of CK20, MAP3K8 and EIF5A correlates with poor prognosis in early-onset colorectal cancer patients. J Cancer Res Clin Oncol2013; 139: 691-702 [PMID: 23322277 DOI: 10.1007/s00432-013-1372-x]
150. 150 McGregor DK, Wu TT, Rashid A, Luthra R, Hamilton SR. Reduced expression of cytokeratin 20 in colorectal carcinomas with high levels of microsatellite instability. Am J Surg Pathol2004; 28: 712-718 [PMID: 15166663]
151. 151 Astrosini C, Roeefzaad C, Dai Y Y, Dieckgraefe BK, Jöns T, Kem-mner W. REG1A expression is a prognostic marker in colorectal cancer and associated with peritoneal carcinomatosis. Int J Cancer2008; 123: 409-413 [PMID: 18452172 DOI: 10.1002/ijc.23466]
152. 152 Zenilman ME, Kim S, Levine BA, Lee C, Steinberg JJ. Ectopic expression of reg protein: A marker of colorectal mucosa at risk for neoplasia. J Gastrointest Surg1997; 1: 194-201; discussion 201-202 [PMID: 9834348]
153. 153 Rechreche H, Montalto G, Mallo GV, Vasseur S, Marasa L, Soubeyran P, Dagorn JC, Iovanna JL. pap, reg Ialpha and reg Ibeta mRNAs are concomitantly up-regulated during human colorectal carcinogenesis. Int J Cancer1999; 81: 688-694 [PMID: 10328217]
154. 154 Sengupta N, Yau C, Sakthianandeswaren A, Mouradov D, Gibbs P, Suraweera N, Cazier JB, Polanco-Echeverry G, Ghosh A, Thaha M, Ahmed S, Feakins R, Propper D, Dorudi S, Sieber O, Silver A, Lai C. Analysis of colorectal cancers in British Bangladeshi identifes early onset, frequent mucinous histotype and a high prevalence of RBFOX1 deletion. Mol Cancer2013; 12: 1 [PMID: 23286373 DOI: 10.1186/1476-4598-12-1]
155. 155 Panarelli NC, Vaughn C P, Samowitz WS, Yantiss RK. Sporadic microsatellite instability-high colon cancers rarely display immu-nohistochemical evidence of Wnt signaling activation. Am J Surg Pathol2015; 39: 313-317 [PMID: 25602793 DOI: 10.1097/PAS.00 00000000000380]
156. 156 Loughrey MB, Waring PM, Tan A, Trivett M, Kovalenko S, Beshay V, Young MA, McArthur G, Boussioutas A, Dobrovic A. Incorporation of somatic BRAF mutation testing into an algorithm for the investigation of hereditary non-polyposis colorectal cancer. Fam Cancer2007; 6: 301-310 [PMID: 17453358]
157. 157 Ak S, Tunca B, Tezcan G, Cecener G, Egeli U, Yilmazlar T, Ozturk E, Yerci O. MicroRNA expression patterns of tumors in early-onset colorectal cancer patients. J Surg Res2014; 191: 113-122 [PMID: 24746948 DOI: 10.1016/j.jss.2014.03.057]
158. 158 Melo SA, Ropero S, Moutinho C, Aaltonen LA, Yamamoto H, Calin GA, Rossi S, Fernandez AF, Carneiro F, Oliveira C, Ferreira B, Liu CG, Villanueva A, Capella G, Schwartz S, Shiekhattar R, Esteller M. A TARBP2 mutation in human cancer impairs microRNA processing and DICER1 function. Nat Genet2009; 41: 365-370 [PMID: 19219043 DOI: 10.1038/ng.317]
159. 159 Martino-Echarri E, Henderson BR, Brocardo MG. Targeting the DNA replication checkpoint by pharmacologic inhibition of Chk1 kinase: a strategy to sensitize APC mutant colon cancer cells to 5-fluorouracil chemotherapy. Oncotarget2014; 5: 9889-9900 [PMID: 25301724]
160. 160 Popat S, Hubner R, Houlston RS. Systematic review of microsate-llite instability and colorectal cancer prognosis. J Clin Oncol2005; 23: 609-618 [PMID: 15659508]
161. 161 Merok MA, Ahlquist T, Røyrvik EC, Tufteland KF, Hektoen M, Sjo OH, Mala T, Svindland A, Lothe RA, Nesbakken A. Microsatellite instability has a positive prognostic impact on stage II colorectal cancer after complete resection: results from a large, consecutive Norwegian series. Ann Oncol2013; 24: 1274-1282 [PMID: 23235802 DOI: 10.1093/annonc/mds614]
162. 162 Violette S, Poulain L, Dussaulx E, Pepin D, Faussat AM, Chambaz J, Lacorte JM, Staedel C, Lesuffeur T. Resistance of colon cancer cells to long-term 5-fluorouracil exposure is correlated to the relative level of Bcl-2 and Bcl-X(L) in addition to Bax and p53 status. Int J Cancer2002; 98: 498-504 [PMID: 11920608]
163. 163 Bishnupuri KS, Luo Q, Murmu N, Houchen CW, Anant S, Dieckgraefe BK. Reg IV activates the epidermal growth factor receptor/Akt/AP-1 signaling pathway in colon adenocarcinomas. Gastroenterology2006; 130: 137-149 [PMID: 16401477]
164. 164 Deng J, Lei W, Fu JC, Zhang L, Li JH, Xiong JP. Targeting miR-21 enhances the sensitivity of human colon cancer HT-29 cells to chemoradiotherapy in vitro. Biochem Biophys Res Commun2014; 443: 789-795 [PMID: 24275137 DOI: 10.1016/j.bbrc.2013.11.064]
165. 165 Institute NC. Targeted Cancer Therapies. [updated 2014 Apr 25]. Rockville, MD: National Cancer Institute, 2014
166. 166 Grothey A, Van Cutsem E, Sobrero A, Siena S, Falcone A, Ychou M, Humblet Y, Bouché O, Mineur L, Barone C, Adenis A, Tabernero J, Yoshino T, Lenz HJ, Goldberg RM, Sargent DJ, Cihon F, Cupit L, Wagner A, Laurent D. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet2013; 381: 303-312 [PMID: 23177514 DOI: 10.1016/S0140-6736(12)61900-X]
167. 167 Van Cutsem E, Tabernero J, Lakomy R, Prenen H, Prausová J, Macarulla T, Ruff P, van Hazel GA, Moiseyenko V, Ferry D, McKendrick J, Polikoff J, Tellier A, Castan R, Allegra C. Addition of afibercept to fuorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. J Clin Oncol2012; 30: 3499-3506 [PMID: 22949147]
168. 168 El Zouhairi M, Charabaty A, Pishvaian MJ. Molecularly targeted therapy for metastatic colon cancer: proven treatments and promising new agents. Gastrointest Cancer Res2011; 4: 15-21 [PMID: 21464866]
169. 169 Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, Bets D, Mueser M, Harstrick A, Verslype C, Chau I, Van Cutsem E. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med2004; 351: 337-345 [PMID: 15269313]
170. 170 Allegra CJ, Jessup JM, Somerfeld MR, Hamilton SR, Hammond EH, Hayes DF, McAllister PK, Morton RF, Schilsky RL. American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. J Clin Oncol2009; 27: 2091-2096 [PMID: 19188670 DOI: 10.1200/JCO.2009.21.9170]
171. 171 Knickelbein K, Zhang L. Mutant KRAS as a critical determinant of the therapeutic response of colorectal cancer. Genes Dis2015; 2: 4-12 [PMID: 25815366]
172. 172 Therkildsen C, Bergmann TK, Henrichsen-Schnack T, Ladelund S, Nilbert M. The predictive value of KRAS, NRAS, BRAF, PIK3CA and PTEN for anti-EGFR treatment in metastatic colorectal cancer: A systematic review and meta-analysis. Acta Oncol2014; 53: 852-864 [PMID: 24666267 DOI: 10.3109/0284186X.2014.895036]
173. 173 French AJ, Sargent DJ, Burgart LJ, Foster NR, Kabat BF, Goldberg R, Shepherd L, Windschitl HE, Thibodeau SN. Prognostic significance of defective mismatch repair and BRAF V600E in patients with colon cancer. Clin Cancer Res2008; 14: 3408-3415 [PMID: 18519771 DOI: 10.1158/1078-0432.CCR-07-1489]
174. 174 Hess GP, Wang PF, Quach D, Barber B, Zhao Z. Systemic Therapy for Metastatic Colorectal Cancer: Patterns of Chemotherapy and Biologic Therapy Use in US Medical Oncology Practice. J Oncol Pract2010; 6: 301-307 [PMID: 21358960 DOI: 10.1200/JOP.2010.000072]
175. 175 Davis SL, Eckhardt SG, Messersmith WA, Jimeno A. The development of regorafenib and its current and potential future role in cancer therapy. Drugs Today (Barc) 2013; 49: 105-115 [PMID: 23462625 DOI: 10.1358/dot.2013.49.2.1930525]
176. 176 Economides AN, Carpenter LR, Rudge JS, Wong V, Koehler-Stec EM, Hartnett C, Pyles EA, Xu X, Daly TJ, Young MR, Fandl JP, Lee F, Carver S, McNay J, Bailey K, Ramakanth S, Hutabarat R, Huang TT, Radziejewski C, Yancopoulos GD, Stahl N. Cytokine traps: multi-component, high-affnity blockers of cytokine action. Nat Med2003; 9: 47-52 [PMID: 12483208]